{"title":"B细胞衰老相关基因作为前列腺癌危险标志物的预后意义。","authors":"Huaiying Zheng, Wei Jiang, Shaoxing Zhu, Xiaobao Chen","doi":"10.21037/tcr-24-724","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prostate adenocarcinoma (PRAD) is a common male urinary system cancer, and its targeted treatment is difficult. This study aimed to investigate the value of B cell senescence-related genes in PRAD prognosis.</p><p><strong>Methods: </strong>PRAD sample expression and clinical information were downloaded from The Cancer Genome Atlas (TCGA) Program and Gene Expression Omnibus (GEO) databases, and B cell senescence-related gene sets were obtained from the Genecards library. The prognostic model was constructed by univariate, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analyses of PRAD differentially expressed genes significantly related to B cell senescence. The Kaplan-Meier (K-M) survival curve and receiver operating characteristic (ROC) curve were drawn to verify the survival rate difference between the high and low risk score groups of the model. The differences of immune characteristics between high and low risk groups were evaluated by single sample gene set enrichment analysis (ssGSEA), ESTIMATE and CIBERSORT. The tumor mutation burden (TMB) score was used to assess the variation in genomic mutations across the groups. Small molecule drugs were screened through the GDSC library. Ultimately, in order to examine the risk assessment model's practicality, a nomogram was created.</p><p><strong>Results: </strong>Three genes <i>WNT16</i>, <i>INS</i> and <i>BMP2</i> related to PRAD progression and B cell senescence were selected to construct a prognostic risk assessment model. The K-M survival curve and ROC curve verified the good performance in evaluating the prognosis of patients. In terms of immune characteristics, the high-risk score group of the model showed a higher overall immune score and immune cell infiltration level, and the high-risk group showed a relatively higher TP53 and TTN mutation frequency. Drug sensitivity analysis showed that the high-risk group had higher resistance to Camptothecin, Cisplatin and WIKI4 drugs. At last, the nomogram that is created using pathological characteristics in conjunction with the risk score can reliably assess the prognosis of patients with PRAD.</p><p><strong>Conclusions: </strong>This study constructed and verified a B cell senescence-related gene model that can predict prognosis of PRAD. More importantly, it provides a reference standard for guiding the prognosis of PRAD patients.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 11","pages":"5771-5783"},"PeriodicalIF":1.5000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651796/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prognostic significance of B cell senescence-associated genes as risk markers in prostate adenocarcinoma.\",\"authors\":\"Huaiying Zheng, Wei Jiang, Shaoxing Zhu, Xiaobao Chen\",\"doi\":\"10.21037/tcr-24-724\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Prostate adenocarcinoma (PRAD) is a common male urinary system cancer, and its targeted treatment is difficult. This study aimed to investigate the value of B cell senescence-related genes in PRAD prognosis.</p><p><strong>Methods: </strong>PRAD sample expression and clinical information were downloaded from The Cancer Genome Atlas (TCGA) Program and Gene Expression Omnibus (GEO) databases, and B cell senescence-related gene sets were obtained from the Genecards library. The prognostic model was constructed by univariate, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analyses of PRAD differentially expressed genes significantly related to B cell senescence. The Kaplan-Meier (K-M) survival curve and receiver operating characteristic (ROC) curve were drawn to verify the survival rate difference between the high and low risk score groups of the model. The differences of immune characteristics between high and low risk groups were evaluated by single sample gene set enrichment analysis (ssGSEA), ESTIMATE and CIBERSORT. The tumor mutation burden (TMB) score was used to assess the variation in genomic mutations across the groups. Small molecule drugs were screened through the GDSC library. Ultimately, in order to examine the risk assessment model's practicality, a nomogram was created.</p><p><strong>Results: </strong>Three genes <i>WNT16</i>, <i>INS</i> and <i>BMP2</i> related to PRAD progression and B cell senescence were selected to construct a prognostic risk assessment model. The K-M survival curve and ROC curve verified the good performance in evaluating the prognosis of patients. In terms of immune characteristics, the high-risk score group of the model showed a higher overall immune score and immune cell infiltration level, and the high-risk group showed a relatively higher TP53 and TTN mutation frequency. Drug sensitivity analysis showed that the high-risk group had higher resistance to Camptothecin, Cisplatin and WIKI4 drugs. At last, the nomogram that is created using pathological characteristics in conjunction with the risk score can reliably assess the prognosis of patients with PRAD.</p><p><strong>Conclusions: </strong>This study constructed and verified a B cell senescence-related gene model that can predict prognosis of PRAD. More importantly, it provides a reference standard for guiding the prognosis of PRAD patients.</p>\",\"PeriodicalId\":23216,\"journal\":{\"name\":\"Translational cancer research\",\"volume\":\"13 11\",\"pages\":\"5771-5783\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651796/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tcr-24-724\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-724","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:前列腺腺癌(PRAD)是一种常见的男性泌尿系统肿瘤,其靶向治疗难度较大。本研究旨在探讨B细胞衰老相关基因在PRAD预后中的价值。方法:从The Cancer Genome Atlas (TCGA) Program和Gene expression Omnibus (GEO)数据库中下载PRAD样本表达和临床信息,从Genecards文库中获取B细胞衰老相关基因集。通过对与B细胞衰老相关的PRAD差异表达基因进行单因素、最小绝对收缩和选择算子(LASSO)和多因素Cox回归分析,构建预后模型。绘制Kaplan-Meier (K-M)生存曲线和受试者工作特征(ROC)曲线,验证模型高、低风险评分组生存率差异。采用单样本基因集富集分析(ssGSEA)、ESTIMATE和CIBERSORT评估高、低危组免疫特性差异。肿瘤突变负荷(TMB)评分用于评估组间基因组突变的差异。通过GDSC文库筛选小分子药物。最后,为了检验风险评估模型的实用性,我们创建了一个nomogram。结果:选择与PRAD进展和B细胞衰老相关的3个基因WNT16、INS和BMP2构建预后风险评估模型。K-M生存曲线和ROC曲线验证了评价患者预后的良好性能。在免疫特性方面,模型高危评分组整体免疫评分和免疫细胞浸润水平较高,高危评分组TP53和TTN突变频率较高。药物敏感性分析显示,高危组对喜树碱、顺铂、WIKI4类药物耐药较高。最后,结合病理特征和风险评分创建的nomogram (nomogram)可以可靠地评估PRAD患者的预后。结论:本研究构建并验证了可预测PRAD预后的B细胞衰老相关基因模型。更重要的是为指导PRAD患者的预后提供了参考标准。
Prognostic significance of B cell senescence-associated genes as risk markers in prostate adenocarcinoma.
Background: Prostate adenocarcinoma (PRAD) is a common male urinary system cancer, and its targeted treatment is difficult. This study aimed to investigate the value of B cell senescence-related genes in PRAD prognosis.
Methods: PRAD sample expression and clinical information were downloaded from The Cancer Genome Atlas (TCGA) Program and Gene Expression Omnibus (GEO) databases, and B cell senescence-related gene sets were obtained from the Genecards library. The prognostic model was constructed by univariate, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analyses of PRAD differentially expressed genes significantly related to B cell senescence. The Kaplan-Meier (K-M) survival curve and receiver operating characteristic (ROC) curve were drawn to verify the survival rate difference between the high and low risk score groups of the model. The differences of immune characteristics between high and low risk groups were evaluated by single sample gene set enrichment analysis (ssGSEA), ESTIMATE and CIBERSORT. The tumor mutation burden (TMB) score was used to assess the variation in genomic mutations across the groups. Small molecule drugs were screened through the GDSC library. Ultimately, in order to examine the risk assessment model's practicality, a nomogram was created.
Results: Three genes WNT16, INS and BMP2 related to PRAD progression and B cell senescence were selected to construct a prognostic risk assessment model. The K-M survival curve and ROC curve verified the good performance in evaluating the prognosis of patients. In terms of immune characteristics, the high-risk score group of the model showed a higher overall immune score and immune cell infiltration level, and the high-risk group showed a relatively higher TP53 and TTN mutation frequency. Drug sensitivity analysis showed that the high-risk group had higher resistance to Camptothecin, Cisplatin and WIKI4 drugs. At last, the nomogram that is created using pathological characteristics in conjunction with the risk score can reliably assess the prognosis of patients with PRAD.
Conclusions: This study constructed and verified a B cell senescence-related gene model that can predict prognosis of PRAD. More importantly, it provides a reference standard for guiding the prognosis of PRAD patients.
期刊介绍:
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.